BIIB-095

N/A

Report date: 2024/04/30 20:00:07
NME

Base Information

Drug NameBIIB-095
Drug Alias NameBIIB-095
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel protein type IX alpha subunit blockers
TargetsSodium channel protein type IX alpha subunit
Therapy Area/IndicationsDiabetic Neuropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen Inc
Active IndicationsN/A
Inactive IndicationsDiabetic Neuropathies

Other Information

ATC CodeN/A
Related LinksN/A